SCHEDULE: Viking Global Discloses 7.8% Stake in Oric Pharma

Viking Global Investors LP and associated entities reported a 7.8% beneficial ownership stake in Oric Pharmaceuticals, Inc. as of March 31, 2026.

Summary

• Viking Global Investors LP (VGI) and affiliated entities report beneficial ownership of 8,264,607 shares of Oric Pharmaceuticals, Inc. common stock.
• The reported stake represents 7.8% of the company's outstanding common stock.
• The holdings consist of direct common stock ownership and pre-funded warrants exercisable at $0.0001 per share.
• David C. Ott has retired from his roles at VGI and is no longer considered a beneficial owner of these shares.
• The filing confirms the investment is held for passive purposes, not to influence control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing institutional interest without signaling a change in strategic direction.

Positives

• Significant institutional backing from a major investment firm, signaling confidence in the company's long-term prospects.
• The investment includes both common stock and pre-funded warrants, providing flexibility in capital structure participation.

Negatives

• The departure of David C. Ott from the reporting group reflects internal management changes at the investment firm level.

Risks

• Market volatility affecting the valuation of biotechnology holdings.
• Regulatory and clinical trial risks inherent to the pharmaceutical industry.
• Potential dilution of ownership percentage if the issuer issues additional shares.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional filings like this are standard in the biotech sector, where large investment firms often maintain significant positions in clinical-stage companies to capitalize on potential drug development breakthroughs.

Comparison to Industry Standards

• The 7.8% stake is consistent with typical institutional ownership levels for mid-cap biotechnology firms.
• The use of pre-funded warrants is a common mechanism for institutional investors to maintain equity exposure in biotech companies while managing capital efficiency.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may view the continued significant stake by Viking Global as a vote of confidence in the company's long-term strategy.

Next Steps

• Continued monitoring of future SEC filings for changes in beneficial ownership.

Key Dates

Keywords

Oric Pharmaceuticals, Viking Global Investors, Schedule 13G, Biotechnology, Institutional Ownership, Common Stock, Warrants